Besponsa vs. Blincyto

• Are Besponsa and Blincyto the Same Thing?
• What Are Possible Side Effects of Besponsa?
• What Are Possible Side Effects of Blincyto?
• What Is Besponsa?
• What Is Blincyto?
• What Drugs Interact with Besponsa?
• What Drugs Interact with Blincyto?
• How Should Besponsa Be Taken?
• How Should Blincyto Be Taken?

Besponsa (inotuzumab ozogamicin) for injection and Blincyto (blinatumomab) are monoclonal antibodies used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Besponsa and Blincyto are different types of monoclonal antibodies. Besponsa is a CD22-directed monoclonal antibody and Blincyto is a CD19-directed CD3 T- cell engager monoclonal antibody.

Side effects of Besponsa and Blincyto that are similar include low platelet counts (thrombocytopenia), low white blood cell counts (neutropenia, leukopenia), infection, anemia, fatigue, bleeding (such as nosebleeds), fever, chills, nausea, vomiting, headache, febrile neutropenia, abdominal pain, diarrhea, and constipation.

Side effects of Besponsa that are different from Blincyto include increased transaminases, swelling and sores inside the mouth, increased gamma-glutamyltransferase, and too much bilirubin in the blood.

Side effects of Blincyto that are different from Besponsa include swelling of extremities, tremor, rash, low blood potassium (hypokalemia), irregular heartbeats (arrhythmia), chest pain, weight gain, decreased appetite, back pain, pain in extremities, bone pain, joint pain, dizziness, insomnia, cough, shortness of breath, and high or low blood pressure (hypertension or hypotension).

Besponsa may interact with drugs known to prolong the QT interval or induce Torsades de Pointes.

Blincyto may interact with warfarin, cyclosporine, or other drugs.

Common side effects of Besponsa include:

• low platelet counts (thrombocytopenia),
• low white blood cell counts (neutropenia, leukopenia),
• infection,
• anemia,
• fatigue,
• bleeding,
• fever,
• nausea,
• headache,
• febrile neutropenia,
• transaminases increased,
• abdominal pain, diarrhea,
• constipation,
• vomiting,
• swelling and sores inside the mouth,
• chills,
• gamma-glutamyltransferase increased, and
• too much bilirubin in the blood

Common side effects of Blincyto include:

• fever
• headache
• swelling of the extremities
• nausea
• tremor
• rash
• constipation
• fever accompanying low levels of white blood cells (febrile neutropenia), and
• low levels of potassium in the blood (hypokalemia)
• anemia
• low platelet levels in the blood
• low white blood cell count
• irregular heartbeats (arrhythmia)
• diarrhea
• abdominal pain
• vomiting
• fatigue
• chills
• chest pain
• infections
• weight gain
• decreased appetite
• back pain
• pain in extremities
• bone pain
• joint pain
• dizziness
• insomnia
• cough
• shortness of breath
• nosebleeds
• high or low blood pressure (hypertension or hypotension)

Besponsa (inotuzumab ozogamicin) for injection is a CD22-directed antibody-drug conjugate (ADC) indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Blincyto (blinatumomab) for injection is a bispecific CD19-directed CD3 T- cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Besponsa may interact with drugs known to prolong the QT interval or induce Torsades de Pointes. Tell your doctor all medications and supplements you use.

Blincyto may interact with warfarin, cyclosporine, or other drugs. Tell your doctor all medications and supplements you use.

The dose and cycle length for Besponsa depends on the cycle, the day of the cycle, and any prior response to treatment. Patients are pre-medicated with a corticosteroid, anti-fever medication, and antihistamine prior to all Besponsa infusions.

Hospitalization is recommended for the first 9 days of the first cycle and the first 2 days of the second cycle of treatment with Blincyto. A single cycle of treatment with Blincyto consists of 4 weeks of continuous intravenous infusion followed by a 2-week treatment-free interval.